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OBJECTIVES: Polycystic Ovary Syndrome (PCOS) is one of the
most common endocrine disorders affecting ﬁve to ten percent of
young women. Aside from its cutaneous symptoms and repro-
ductive morbidity, PCOS associates with metabolic syndrome
and an increased risk of cardiovascular events. In recent years the
use of Metformin, an insulin sensitizer, in PCOS has aroused a
great interest. Metformin administration restores ovulatory men-
strual cycles and seems to improve infertility. However, the extent
to which this agent improves the metabolic and cardiovascular
risk factors associated with PCOS remains uncertain. Our aim
was to assess the effectiveness of Metformin in improving clinical
and metabolic features of PCOS. METHODS: Systematic
Review (up to February 2008) and meta-analysis of randomized
controlled trials that compared Metformin versus placebo or
other standard therapies for PCOS such as oral contraceptive
pills (OCPs) and measured metabolic and cardiovascular param-
eters. Studies were critically appraised. Pooled estimates of effect
were based on a random-effects model. Odds Ratio and
Weighted Mean Difference, with 95% conﬁdence interval, used
were appropriate. Consistency across studies was evaluated by
means of the I-square statistic. Potential reasons for heterogene-
ity were explored. RESULTS: Of 120 candidate studies, 19 trials
were eligible. Methodological quality of these trials was low.
Meta-analyses showed a small decrease in BMI and systolic
blood pressure in women treated with Metformin compared to
placebo. The other parameters including waist circumference,
waist-hip ratio, diastolic blood pressure, fasting blood glucose,
insulin levels and lipid proﬁle did not differ between the groups.
As against OCPs, Metformin signiﬁcantly reduced the BMI but
no other signiﬁcant differences were observed. CONCLUSIONS:
Scant and inconsistent evidence suggest that Metformin provide
limited or no important beneﬁt for metabolic derangements and
cardiovascular risk factors in women with PCOS. Further
research is needed to solve this important health issue.
PCV101
PROSPECTIVE STUDYTO EVALUATETHE IMPACT OF A
DISEASE EDUCATION PROGRAM OF CARDIOVASCULAR RISK
CONTROL IN HYPERTENSION
Galera J1, Salazar J1,Armario P2, Segura J3
1Novartis Farmacéutica S.A, Barcelona, Spain, 2Hospital General de
L’Hospitalet, L’Hospitalet de Llobregat (Barcelona), Spain, 3Hospital 12
de Octubre, Madrid, Spain
OBJECTIVES: To evaluate the effectivity of an education
program, measuring the percentage of patients with blood pres-
sure control at the end of a follow-up period in comparison to
baseline. METHODS: Prospective and multicentric study real-
ized in Hypertension Units (HU) and Primary Care (PC) centers
in Spain. Physicians included outpatients 18 years with not
controlled essential hypertension (BP > 140/90 or BP > 130/
80 mmHg if diabetic or previous CV events and BP < 180/
110 mmHg). Patients were followed for ﬁve months in four
scheduled visits. At V0 blood pressure, patient demographics,
medical and drug history, CV risk factors and lifestyle were
assessed using standardized methods. Between V0 and V1 the
intervention consists in medical education for physicians on CV
risk control and guidelines. During V1 and V2 patients received
education and support. At V3 we assessed the overall interven-
tion in BP control. Informed consent was obtained. RESULTS: A
total of 316 patients were recruited, 64.2% in PC and 35.8% in
HU centers (62.8  12.1 years, 51.6% males, BMI 29.8 
5.1 Kg/m2). Mean ofﬁce BP was 156.0  14.3/89.4  10.9
(mean AMPB daytime 141.4  12.7/86.5  11.3) mmHg at
baseline. Obesity (60.6%), dyslipemia (53.4%), type-2 diabetes
(23.1%), target organ damage (16.6%), smoking habits (16.6%)
and coronary artery disease (12.8%) were the most prevalent CV
risk factors. A total of 82.4% of patients completed satisfactorily
the intervention. Mean BP had a decreasing trend along the
study: at V1 mean BP was 143.1  16.9/82.8  11.5, at V2 was
137  13.1/79,5  9.1 and at V3 was 135.0  12.4/77,8  8.8.
At the end of the study 52.7% of patients reach the BP goal
during the 5–month intervention study. CONCLUSIONS: Based
on this results, medical and patient education determine a greater
BP control, hence more educational actions are needed to
increase BP control.
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COST-EFFECTIVENESS OF MANAGING ORAL
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OBJECTIVES: PAAF is becoming an increasingly common thera-
peutic procedure for symptomatic AF. Until recently, oral anti-
coagulation regimens remained in place even after a successful
ablative procedure. Recent clinical debate, however, suggests that
oral anticoagulation could be discontinued after an ablation,
should the patient be free from AF. ICMs can be used immedi-
ately after the ablation procedure to verify freedom from asymp-
tomatic AF recurrence. If the patient remains free from
symptomatic and asymptomatic AF recurrences, OAC may be
discontinued. The ICM will also alert the patient of any recur-
rences after OAC has been stopped. In this way, OAC can be
restarted if needed. We sought to examine the cost-effectiveness
of this OAC management strategy. METHODS: We developed a
Markov Decision Analytic Model in TreeAge Pro Version 8 for
Health care. Literature searches were performed for risk of AF
recurrence; risk of stroke; risk of OAC adverse effects; and, risks
of anti-arrhythmic adverse effects. Utilities for the various health
states were also found in the literature. Costs were based of the
UK NHS. RESULTS: Using ICM to manage oral anticoagulation
proved cost-effective within the three-year lifespan of the device.
The ICER was estimated at £27,582 per QALY gained. CON-
CLUSIONS: Managing oral anticoagulation in this patient popu-
lation is a newly developed concept. This strategy has the
potential to allow individuals restricted in their daily activities by
OAC treatment to resume their normal lives. Our analysis has
shown that OAC management can be cost-effective. Further
work is needed to assess the cost-effectiveness implications over
a longer timeframe and to identify the patient subgroups where
the economic beneﬁts of OAC management are maximized.
PCV103
TECHNOLOGICAL INNOVATION ANDTHE
DECISION-MAKING PROCESS IN ITALIAN HOSPITALS
Bartoli S1,Tarricone R1, Benussi S2, Stefano P3, Marinelli G4
1Bocconi University, Milan, Italy, 2S Raffaele University Hospital, Milan,
Italy, 3Careggi University-Hospital, Firenze, Italy, 4Sant’Orsola-Malpighi
University-Hospital, Bologna, Italy
OBJECTIVES: This paper aims at discussing hospital managers’
consideration of costs vs. tariffs (i.e. DRGs) when decisions on
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technological innovation have to be taken. To reach this goal, the
paper takes a case-study approach, i.e. surgical ablation (SA)
performed in concomitance with cardiac surgery procedures.
METHODS: An observational, retrospective, multi-centre study
was carried out. Three hospitals were selected based upon the
volume of activity (i.e. >50 SA procedures/year). Patients
(N = 311) were enrolled during a 16-month period and recruited
if they met inclusion criteria. Health care resource consumption
was measured in detail through a bottom-up micro-costing
approach. RESULTS: Direct and full costs of SA and of the
concomitant cardiac surgery procedures were calculated per
patient by using a standard costing approach. Mean direct cost of
surgical interventions (SA and the concomitant procedures) is
€9093 (range: 6406–14,746). While there is a large homogeneity
among centres as to costs of SA (mean €1889), signiﬁcant differ-
ences (p < 0.05) emerge in costs of concomitant interventions
(mean €7204) mainly because of different organisational pat-
terns. CONCLUSIONS: Hospital managers are struggling to face
the tension between scarcity of resources and increasing health
care needs. Technological innovation opens new opportunities
for hospital activities and patients’ health that however need to
be assessed against its costs. Which cost (i.e. direct vs. full
costing) is to be considered in the decision-making process
however is still not clear. There is a tendency to consider full
costing of new procedures and to decide whether they are ﬁnan-
cially sustainable by contrasting it to the relevant DRG(s).
Nevertheless, it is here argued that ﬁrstly, direct costing better
illustrates the true economic value of the innovative procedures
and therefore should be primarily used, and secondly, ﬁnancial
hospital sustainability would need to be assessed based upon
hospitals’ case-mix and not in silos.
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OBJECTIVES: Drug therapy should be appropriately prescribed
and administered in order to efﬁcaciously prevent cardiovascu-
lar events. The study aim was to describe the prescriptions of
statins in terms of persistence and compliance with the purpose
of identiﬁng appropriate pharmaco-epidemiological indicators
close to clinical practice. METHODS: Statins (ATC C10AA)
prescriptions data were collected from administrative databases
in two Local Health Units (LHUs) in Northern Italy. Eligible
patients should have had at least one statin prescription in three
consecutive years (2004–2006). The adopted indicators for drug
utilization included: “Calendar Days (CD)”, calculated as the
difference between the last and the ﬁrst prescription dates in
each year; “PDD days (PDDd)”, calculated as the ratio between
total mg prescribed and the surrogated prescribed daily doses;
“DDD days (DDDd)”, calculated as the ratio between total mg
prescribed and the deﬁned daily dose. A Compliance to Therapy
Index (CTI) was calculated as the ratio between the total PDDd
and the CD: indexes were calculated for each patient and clas-
siﬁed in four compliance categories (25%, >25% & 50%,
50% & 75%, >75% & 100%). RESULTS: Indicators
showed an increase in statins use over the study period in terms
of both DDD and sPDD. Persistence to therapy for at least two
years was around 50% in both LHUs. PDDd was a more reli-
able measure of the daily dosage in comparison with DDDd,
which resulted in a coverage period longer than the CD. CTI
analysis showed a decrease in low compliance categories
(patients in the range 25%–50% decreased from 26% to 17%)
and a raise in the rate of compliant patients (from 48% to
57%). Single prescriptions increased from 1% to 5%. CON-
CLUSIONS: Although statins’ use is steadily growing, poor
patients’ persistence and adherence to therapy would need the
implementation of strategies to improve compliance with lipid
lowering medications.
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OBJECTIVES: Cardiovascular drugs account for 40% of total
outpatient drug utilization in the City of Zagreb. Among them,
utilization of the group of hypolipemics showed greatest rise
from 2001 to 2006. The aim of the study was to investigate
outpatient utilization of hypolipemics in the City of Zagreb
during the 2001–2006 period and to assess the quality of pre-
scribing these drugs in primary health care. METHODS: The
number of deﬁned daily doses (DDD) and DDD per 1000 Zagreb
inhabitants per day (DDD/1000/day) were calculated on the
basis of data on the number of packages of each individual
hypolipemic (C10) for each study year. Data on the rate of
hospitalization for the leading cardiovascular complications were
collected as indirect indicators of the quality of prescribing
statins. RESULTS: The utilization of hypolipemics was 33.03
DDD/1000/day in 2001 and 72.38 DDD/1000/day in 2006,
yielding an almost twofold rise. Two drugs, simvastatin and
atorvastatin, predominated in the utilization of statins with 93%.
From 2001 to 2006, the utilization of simvastatin showed a 30%
increase and that of atorvastatin more than sevenfold increase.
During the study period, the overall rate of hospitalization for
cardiovascular disorders decreased by 18.5%. CONCLUSIONS:
The decreasing tendency recorded in hospitalization for cardio-
vascular diseases points to the improved quality of secondary
prevention, including statins. The growing trend observed in the
utilization of atorvastatin vs. simvastatin is indicative of the still
inappropriate prescribing practice, whereas the high rate of hos-
pitalization for hypertension reﬂects inadequate primary preven-
tion of cardiovascular disorders.
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OBJECTIVES: This study examined the effect of Octylcyanoac-
rolate topical skin adhesive (DERMABOND Topical Skin
Adhesive) on the risk of surgical site infection (SSI) and other
clinical outcomes and resource utilization in patients undergo-
ing coronary artery bypass graft (CABG) surgery. METHODS:
This study utilized the Premier Perspective(tm) Comparative
Database, which includes over ﬁce million hospital discharges
per year. Qualifying patients who underwent CABG surgery
during 2005 and 2006 were identiﬁed. Patients were classiﬁed
into four groups by method of surgical wound closure (sutures
only; sutures/DERMABOND; sutures/staples; and sutures/
staples/DERMABOND). The primary study outcome was the
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